MIAMI — A protein that targets tissue factor in neovascular age-related macular degeneration was well tolerated in a phase 1 study, a speaker told colleagues here. Carl D. Regillo, MD, reviewed results of a phase 1 study of ICON-1 (Iconic Therapeutics) in the treatment of neovascular AMD at Angiogenesis, Exudation, and Degeneration 2016.
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful 12-month interim safety results of Rocket 2, Aerie’s second Phase 3 registration trial for RhopressaTM (netarsudil ophthalmic solution) 0.02%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with gl
A new study has shown a significant association between retinal hemorrhage and anticoagulant or antiplatelet use in patients who have neovascular age-related macular degeneration and hypertension. Medscape Medical News
Ocular Therapeutix is planning to initiate the first of two phase 3 clinical trials of OTX-TP for the treatment of glaucoma and ocular hypertension in the third quarter based on feedback from a recent meeting with the FDA, the company announced in a pr…
Novaliq has started to enroll patients in a phase 2 trial of CyclASol to treat dry eye disease, the company announced in a press release. The randomized, double-masked, placebo-controlled multicenter phase 2 trial will evaluate the safety, efficacy and…
A newly updated guide from the American Geriatrics Society (AGS) and the National Highway Traffic Safety Administration (NHTSA) is putting healthcare professionals on the road to success for…